Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 07-22 20:36:36时区推断·⟳ 抓取 07-22 20:39:47·⚡ 决策 07-23 08:35:07 +11h55m·96.5 天前
Tempus AI全国推出OneOme药物基因组检测
OneOme推出27基因RightMed Comprehensive及DPYD、UGT1A1单基因检测，属于产品线扩展而非已披露订单。
📄 原文Investing.com↗ 原文
Tempus AI launches pharmacogenomics testing nationwide
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven? CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) an…
不做 Tempus AI（TEM.US）
产品发布未披露检测量、价格、客户或收入增量，相对84.32亿美元市值太软，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司宣布全国推出OneOme药物基因组检测，正文未披露订单、售价或客户量。市场反应:TEM.US 2026-07-22收跌4.12%。
关键理由
- OneOme推出27基因RightMed Comprehensive及DPYD、UGT1A1单基因检测，属于产品线扩展而非已披露订单。
- TEM.US市值约84.32亿美元，本次未披露价格、客户、检测量或收入增量，短线难形成市值级重定价。
主要风险
- 公司近期股价5日下跌17.97%，且两天前Personalis收购带来股本摊薄和整合关注，容易压过该产品发布。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-21 · 影响 weakens
近期15亿美元收购和股价下跌是更强的反向因素。
检索:Tempus AI Personalis acquisition stock falls dilution July 2026 原文 ↗
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,820 字
Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced today the national launch of its OneOme pharmacogenomics testing solution, which analyzes genetic factors affecting medication safety and dosing, according to a company press release.
The launch introduces OneOme’s RightMed Comprehensive test, a 27-gene germline pharmacogenomics laboratory developed test, along with standalone single-gene DPYD and UGT1A1 testing options. The tests evaluate how a patient’s genetic profile may influence their response to medications, toxicity risk, and optimal dosage across various therapies.
Tempus acquired OneOme in November 2025 and has integrated the pharmacogenomics capabilities into its precision medicine portfolio. The testing delivers results in under five days on average from sample receipt.
The FDA updated safety labeling on February 5, 2026, recommending DPYD testing prior to administering fluoropyrimidine therapies. Research indicates nearly 30% of patients receiving these treatments experience severe toxicities.
"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative, particularly in oncology care," said Tom Schoenherr, CEO of Diagnostics at Tempus.
The testing solution integrates with Tempus’s existing platform, allowing clinicians to evaluate drug-gene interactions alongside tissue and liquid biopsy sequencing.
Tempus describes itself as a technology company advancing precision medicine through artificial intelligence applications in healthcare. The company maintains a library of multimodal data and provides AI-enabled precision medicine solutions to physicians.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced today the national launch of its OneOme pharmacogenomics testing solution, which analyzes genetic factors affecting medication safety and dosing, according to a company press release.
The launch introduces OneOme’s RightMed Comprehensive test, a 27-gene germline pharmacogenomics laboratory developed test, along with standalone single-gene DPYD and UGT1A1 testing options. The tests evaluate how a patient’s genetic profile may influence their response to medications, toxicity risk, and optimal dosage across various therapies.
Tempus acquired OneOme in November 2025 and has integrated the pharmacogenomics capabilities into its precision medicine portfolio. The testing delivers results in under five days on average from sample receipt.
The FDA updated safety labeling on February 5, 2026, recommending DPYD testing prior to administering fluoropyrimidine therapies. Research indicates nearly 30% of patients receiving these treatments experience severe toxicities.
"Answering the urgent demand for immediate, reliable medication safety insights is a clinical imperative, particularly in oncology care," said Tom Schoenherr, CEO of Diagnostics at Tempus.
The testing solution integrates with Tempus’s existing platform, allowing clinicians to evaluate drug-gene interactions alongside tissue and liquid biopsy sequencing.
Tempus describes itself as a technology company advancing precision medicine through artificial intelligence applications in healthcare. The company maintains a library of multimodal data and provides AI-enabled precision medicine solutions to physicians.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。